Clinical Trial Update: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

This document provides a clinical trial update on a Phase 3 study evaluating AK104 in combination with platinum-containing chemotherapy, with or without bevaciz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)

Snippet

Sponsor: Akeso | Conditions: Cervical Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING